Twist Bioscience officer sells 14,205 shares

Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 14,205 shares of Common Stock at $69.75 per share.

Rhea-AI Filing Summary

Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 14,205 shares of Common Stock at $69.75 per share. The transaction occurred on May 29, 2026 and was executed under a pre-established Rule 10b5-1 trading plan adopted on May 7, 2025.

After this sale, Cho directly holds 120,094 Twist Bioscience shares, indicating the transaction represents only a portion of his overall ownership. Because the trade was made pursuant to a Rule 10b5-1 plan, its timing reflects a pre-planned arrangement rather than a discretionary decision based on near-term company developments.

Insider Trade Summary 10b5-1

Net Seller: 14,205 shares

Net Sell 1 txn

Insider Cho Dennis

Role See Remarks

Sold 14,205 shs ($991K)

Type	Security	Shares	Price	Value
Sale	Common Stock	14,205	$69.75	$991K

Holdings After Transaction: Common Stock — 120,094 shares (Direct)

Footnotes (1)

1. F1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 7, 2025.

Key Figures

Shares sold: 14,205 shares Sale price: $69.75 per share Shares held after sale: 120,094 shares +2 more

5 metrics

Shares sold 14,205 shares Open-market sale of Common Stock on May 29, 2026

Sale price $69.75 per share Price for the 14,205 shares sold

Shares held after sale 120,094 shares Direct ownership following the reported transaction

Trade plan adoption date May 7, 2025 Date Dennis Cho adopted Rule 10b5-1 trading plan

Transaction type Open-market sale Form 4 non-derivative transaction in Common Stock

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for the Common Stock transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock" in the reported non-derivative transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Twist Bioscience (TWST) officer Dennis Cho report in this Form 4?

Dennis Cho reported an open-market sale of 14,205 shares of Twist Bioscience Common Stock. The transaction was executed at $69.75 per share and reflects a partial reduction of his holdings, not a complete exit from his position.

How many Twist Bioscience (TWST) shares does Dennis Cho hold after the sale?

After the reported transaction, Dennis Cho directly holds 120,094 shares of Twist Bioscience Common Stock. This shows that the 14,205 shares sold represent only part of his stake, with a substantial share position remaining following the sale.

Was Dennis Cho’s Twist Bioscience (TWST) share sale pre-planned?

Yes. The filing states the sale was made under a Rule 10b5-1 trading plan adopted on May 7, 2025. Such plans pre-schedule trades, meaning the timing of this May 29, 2026 sale was set in advance rather than decided opportunistically.

What was the sale price in Dennis Cho’s Twist Bioscience (TWST) transaction?

The Form 4 reports that Dennis Cho sold 14,205 shares of Twist Bioscience Common Stock at $69.75 per share. This price reflects the average transaction price for the open-market sale executed on May 29, 2026 under his trading plan.

Does the Form 4 for Twist Bioscience (TWST) show any option exercises?

No. The disclosed activity involves only a non-derivative transaction in Common Stock. The derivative section shows no remaining derivative positions, and the transaction summary reports zero derivative exercises during this reporting event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		S		14,205(1)	D	$69.75	120,094	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 7, 2025.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)